1. 1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results. (15th December 2022) Authors: Ogbuagu, Onyema; Segal-Maurer, Sorana; Ratanasuwan, Winai; Trottier, Benoit; Brunetta, Jason; Shirasaka, Takuma; Koenig, Ellen L; Wang, Hui; Margot, Nicolas A; Dvory-Sobol, Hadas; Rhee, Martin S; Baeten, Jared; Molina, Jean-Michel Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 937. Virally Suppressed PLH Switching From Abacavir to Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation. (26th November 2018) Authors: Funderburg, Nicholas; Mccomsey, Grace; Kulkarni, Manjusha; Bowman, Emily R; Gabriel, Janelle; Snyder, Brandon; Mallon, Patrick; Winston, Alan; Sengupta, Devi; Yan, Mingjin; Rhee, Martin S; Das, Moupali Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Issue 4 (April 2016) Authors: Gallant, Joel E; Daar, Eric S; Raffi, François; Brinson, Cynthia; Ruane, Peter; DeJesus, Edwin; Johnson, Margaret; Clumeck, Nathan; Osiyemi, Olayemi; Ward, Doug; Morales-Ramirez, Javier; Yan, Mingjin; Abram, Michael E; Plummer, Andrew; Cheng, Andrew K; Rhee, Martin S Journal: Lancet Issue: Volume 3:Issue 4(2016) Page Start: e158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study. (4th October 2017) Authors: Flamm, Jason A; Vanig, Thanes; Gathe, Joseph; Kinder, Clifford; Para, Michael; Rashbaum, Bruce; Segal-Maurer, Sorana; Shamblaw, David; Wohlfeiler, Michael; Young, Benjamin; Zurawski, Christine; Rhee, Martin S Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Issue 1 (January 2023) Authors: Gupta, Samir K; Berhe, Mezgebe; Crofoot, Gordon; Benson, Paul; Ramgopal, Moti; Sims, James; McDonald, Cheryl; Ruane, Peter; Sanchez, William E; Scribner, Anita; Liu, Shan-Yu; VanderVeen, Laurie A; Dvory-Sobol, Hadas; Rhee, Martin S; Baeten, Jared M; Koenig, Ellen Journal: Lancet Issue: Volume 10:Issue 1(2023) Page Start: e15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir. (9th September 2022) Authors: Margot, Nicolas A; Naik, Vidula; VanderVeen, Laurie; Anoshchenko, Olena; Singh, Renu; Dvory-Sobol, Hadas; Rhee, Martin S; Callebaut, Christian Journal: Journal of infectious diseases Issue: Volume 226:Number 11(2022) Page Start: 1985 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Issue 12 (December 2016) Authors: Gaur, Aditya H; Kizito, Hilda; Prasitsueubsai, Wasana; Rakhmanina, Natella; Rassool, Mohammed; Chakraborty, Rana; Batra, Jagmohan; Kosalaraksa, Pope; Luesomboon, Wicharn; Porter, Danielle; Shao, Yongwu; Myers, Michael; Ting, Lillian; SenGupta, Devi; Quirk, Erin; Rhee, Martin S Journal: Lancet Issue: Volume 3:Issue 12(2016) Page Start: e561 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. (September 2017) Authors: Natukunda, Eva; Gaur, Aditya H; Kosalaraksa, Pope; Batra, Jagmohan; Rakhmanina, Natella; Porter, Danielle; Shao, Yongwu; Zhang, Heather; Pikora, Cheryl; Rhee, Martin S Journal: Lancet Issue: Volume 1:Number 1(2017) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. Issue 4 (April 2018) Authors: Winston, Alan; Post, Frank A; DeJesus, Edwin; Podzamczer, Daniel; Di Perri, Giovanni; Estrada, Vicente; Raffi, François; Ruane, Peter; Peyrani, Paula; Crofoot, Gordon; Mallon, Patrick W G; Castelli, Francesco; Yan, Mingjin; Cox, Stephanie; Das, Moupali; Cheng, Andrew; Rhee, Martin S Journal: Lancet Issue: Volume 5:Issue 4(2018) Page Start: e162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients. Issue 3 (April 2015) Authors: White, Kirsten L; Kulkarni, Rima; McColl, Damian J; Rhee, Martin S; Szwarcberg, Javier; Cheng, Andrew K; Miller, Michael D Journal: Antiviral therapy Issue: Volume 20:Issue 3(2015) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗